Redeye comments on Medivir's Q3 report. We make changes to our base case as IGM Biosciences exits oncology, and a median time to progression of 10.9 months for fostrox has been established.
ANNONS
Redeye comments on Medivir's Q3 report. We make changes to our base case as IGM Biosciences exits oncology, and a median time to progression of 10.9 months for fostrox has been established.